The original instrument was prepared by Christine Arbo Peck. The following digest, which does not constitute a part of the legislative instrument, was prepared by Mary Dozier O'Brien.

DIGEST 2016 Regular Session

SB 117 Reengrossed

Mills

<u>Present law</u> includes legislative intent that was added in 2006 after implementation of Medicare Part D and post-Hurricane Katrina. <u>Proposed law</u> removes <u>present law</u>.

<u>Present law</u> includes a restriction on implementation of provisions of <u>present law</u> for a period of six months after June 13, 2001. <u>Proposed law</u> removes <u>present law</u>.

<u>Present law</u> includes provisions that were sunset by subsequent law. <u>Proposed law</u> removes the provisions that were sunset.

<u>Present law</u> requires membership of the committee to be selected from a list of three names submitted by each represented organization. <u>Proposed law</u> allows each represented organization to submit one name as their representative.

<u>Present law</u> provides that two practicing pharmacists shall be selected from a list of names submitted by the Louisiana Pharmacists Association. <u>Proposed law</u> changes the committee appointment members for the two practicing pharmacist positions to require that one member shall be an independent pharmacist recommended by the Louisiana Independent Pharmacies Association and one member shall be a pharmacist representing a chain pharmacy recommended by the Louisiana Pharmacists Association.

<u>Present law</u> refers to the Medicaid pharmacy drug list as a pharmacopia. <u>Proposed law</u> changes the reference to preferred drug list.

<u>Present law</u> provides that new drugs are available on the pharmacopia as soon as they are approved by the USDA and commercially available. <u>Proposed law</u> states that new drugs may be added when approved by the USDA and the manufacturer enters into a federal medicaid drug rebate program if the department determines it is in the best interest of the medical assistance program.

<u>Proposed law</u> clarifies that when a new drug reviewed by the committee is approved by the FDA, it shall be reviewed at the next committee meeting.

Effective upon signature of the governor or lapse of time for gubernatorial action.

(Amends R.S. 46:153.3(B)(2)(a)(iv), (D)(2)(intro para), (D)(2)(c), (d), (e), (f), (g), (h), (k), and (p), and (D)(5)(b) and (c); repeals R.S. 46:153.3(B)(1)(b), (c), (d), and (e), (B)(2)(d), (B)(3) and (4), (C)(2) and (3), and (D)(5)(d) and (e))

Summary of Amendments Adopted by Senate

<u>Committee Amendments Proposed by Senate Committee on Health and Welfare to the</u> original bill

- 1. Changes the committee appointment members for the two practicing pharmacist positions to require that one member shall be an independent pharmacist recommended by the Louisiana Independent Pharmacies Association and one member shall be a pharmacist representing a chain pharmacy recommended by the Louisiana Pharmacists Association.
- 2. Clarifies that when a new drug is approved by the FDA, it shall be reviewed for consideration by the committee at their next scheduled meeting for consideration of inclusion on the preferred drug list.
- 3. Makes technical changes.

Senate Floor Amendments to engrossed bill

1. Adopted amendments from Legislative Bureau note that were purely technical.